Search results for: 'Biological antibody reagents US'

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

AI has moved from a standalone technology to a core building block that drives global business growth. AI adoption is increasingly critical for international businesses to stay competitive. Improved efficiency and productivity and the need to gain a competitive edge drive the rising adoption of AI among businesses. Understanding AI use cases and a...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights into recent technological developments for molecular marker detection, drug delivery, cancer immunotherapies and radiopharmaceuticals. The TOE also comprises analysis of innovations across cell and gene therapy, antibody and gene editing platfo...

The COVID-19 pandemic led to the rapid scaling up of production activities in the pharmaceutical industry. An increase in the number of FDA approvals in biologics has further accelerated biopharmaceutical production, particularly in North America and Asia. With a boom in biopharmaceuticals anticipated in the next 5 to 7 years, the demand for single...

This Frost & Sullivan research service focuses on US Department of Defense (DoD) satellite growth budget spending and contracts. The study includes research, development, test, and evaluation (RDT&E); procurement; operations and maintenance (O&M); and other services. Satellite spending for the fiscal year 2025 DoD budget request is the foundati...

The US life sciences research tools market encompasses analytical tools, instruments, consumables, reagents, and services (e.g., X-rays and sample preparation). Tools include laboratory automation and technologies that provide molecular insight into disease mechanisms and enable novel therapeutic and medical device development to improve human heal...

The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies towa...

The United States economic growth remained buoyant throughout 2023 amid stronger-than-expected consumer spending and falling inflation. However, Frost & Sullivan expects real gross domestic product (GDP) growth to slow from 2.5% in 2023 to 2.2% in 2024 amid the delayed effects of monetary policy tightening on domestic spending. The United States w...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) comprise innovation insights across antibody and cellular therapies. The study also encompasses recent innovations in liquid biopsy tests, drug delivery and drug discovery platforms.The Life Science, Health & Wellness TOE will feature disruptive technology advan...